<DOC>
	<DOCNO>NCT00093119</DOCNO>
	<brief_summary>This trial treat patient previously treat advanced ( metastatic ) melanoma ( skin cancer ) new chemotherapeutic medicine . The new chemotherapy administer weekly cycle three weekly dos follow one week rest . A minimum three cycle therapy give determine anti-tumor response new chemotherapy . Patients may continue stay therapy maximum 9-12 cycle treatment show continue benefit .</brief_summary>
	<brief_title>Trial ABI-007 Previously Treated Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Confirmed Metastatic Melanoma At least 18 year old No active malignancy Hemoglobin least 9 Platelet Count least 100,000 cells/mm3 ANC least 1500 cells/mm3 AST &amp; ALT le 2.5X upper limit normal Total bilirubin le 1.5mg/dL Creatine less 1.5 mg/dL Alkaline phosphatase le 2.5X upper limit normal Life expectancy least 12 week ECOG performance status 01 Patient must provide informed consent Patient must provide authorization disclose Evidence active brain metastases The evidence metastasis lytic blastic bone metastasis Preexisting peripheral neuropathy NCI Toxicity Criteria Scale grade great 2 Received radiotherapy last 4wks , except nontarget lesion Clinically significant concurrent illness Investigator 's opinion patient unlikely complete study Cytotoxic chemotherapeutic agent treatment investigational drug within previous 4wks History allergy/hypersensitivity study drug Serious Medical Risk Factors determine investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>Metastatic Melanoma</keyword>
</DOC>